🔎 Trials Near Me

Home › Breast Cancer › Massachusetts › Boston

Breast Cancer clinical trials in Boston, MA

110 studies for Breast Cancer are looking for participants at sites in and around Boston (within about 30 miles). Open a study to see who can join and how to contact the study team.

Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →

Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

RecruitingPhase 3
  • Massachusetts General Hospital, Boston
  • Dana-Farber Cancer Institute, Boston
Ages 18 and older · All sexes · Updated Nov 13, 2026 · NCT05696626

Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.

RecruitingPhase 1/2
  • Research Facility, Boston
All ages · All sexes · Updated Nov 12, 2026 · NCT06590857

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

RecruitingPhase 3
  • Massachusetts General Hospital Cancer Center ( Site 0091), Boston
  • Dana Farber Cancer Institute ( Site 0090), Boston
Ages 18 and older · All sexes · Updated Nov 10, 2026 · NCT06966700

Prospective Screening for Breast Cancer-related Lymphedema

RecruitingObservational study
  • Massachusetts General Hospital, Boston
Ages 18 and older · Women · Updated Nov 10, 2026 · NCT01521741

Screening For BCRL In Targeted Therapy For Breast Cancer

RecruitingObservational study
  • Massachusetts General Hospital, Boston
Ages 18 to 80 · Women · Updated Nov 10, 2026 · NCT05142800

The COMPASSION Study

Recruiting
  • Dana-Farber Cancer Institute, Boston
Ages 18 and older · All sexes · Updated Nov 10, 2026 · NCT06507930

A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors

RecruitingPhase 1
  • Dana-Farber Cancer Institute, Boston
Ages 18 and older · All sexes · Updated Nov 5, 2026 · NCT07029399

Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer

Recruiting
  • Massachusetts General Hospital, Boston
Ages 18 and older · All sexes · Updated Nov 5, 2026 · NCT07214532

Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

RecruitingPhase 1/2
  • Dana Farber Cancer Institute, Boston
Ages 18 and older · All sexes · Updated Nov 5, 2026 · NCT05315700

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

RecruitingPhase 3
  • Tufts Medical Center, Boston
  • Dana Farber Cancer Institute, Boston
Ages 18 and older · All sexes · Updated Nov 5, 2026 · NCT06982521

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

RecruitingPhase 3
  • Mass General Cancer Center, Boston
  • Dana-Farber Cancer Institute, Boston
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT07174336

E-Mindfulness Approaches for Living After Breast Cancer

RecruitingPhase 3
  • Tufts Medical Center, Boston
  • Dana-Farber Cancer Institute, Boston
Ages 18 to 50 · All sexes · Updated Nov 4, 2026 · NCT06748222

A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer

RecruitingPhase 2
  • Massachusetts General Hospital, Boston
  • Dana-Farber Cancer Institute, Boston
Ages 18 and older · Women · Updated Nov 4, 2026 · NCT07287098

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

RecruitingPhase 1/2
  • Massachusetts General Hospital, Boston
  • Dana Farber Cancer Institute, Boston
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT05579366

A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

RecruitingPhase 1
  • Massachusetts General Hospital, Boston
  • Beth Israel Deaconess Medical Center, Boston
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT07213791

A Study of LY4257496 in Participants With Cancer (OMNIRAY)

RecruitingPhase 1
  • Massachusetts General Hospital, Boston
  • Dana-Farber Cancer Institute, Boston
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT07114601

Distance-Based Exercise to Preserve Function and Prevent Disability

Recruiting
  • Dana-Farber Cancer Institute, Boston
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT07059884

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

RecruitingPhase 3
  • Tufts Medical Center, Boston
  • Beth Israel Deaconess Medical Center, Boston
  • Dana-Farber Cancer Institute, Boston
Ages 18 to 60 · Women · Updated Nov 4, 2026 · NCT05879926

A Study of JNJ-101684362 (HLD-0117) in Patients With Metastatic Breast Cancer

RecruitingPhase 1
  • Massachusetts General Hospital, Boston
Ages 18 and older · Women · Updated Nov 3, 2026 · NCT07524855

A Phase 1 Study of IM-1617 in Participants With Advanced Cancer

RecruitingPhase 1
  • Massachusetts General Hospital, Boston
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT07578571

The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

RecruitingPhase 3
  • Dana-Farber Cancer Institute, Boston
Ages 60 and older · All sexes · Updated Nov 2, 2026 · NCT06377852

A Phase 1 Study of LNCB74 in Advanced Solid Tumors

RecruitingPhase 1
  • Dana Farber Cancer Institute, Boston
Ages 18 and older · All sexes · Updated Oct 29, 2026 · NCT06774963

A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer

RecruitingPhase 2
  • Dana Farber Cancer Institute, Boston
Ages 18 and older · All sexes · Updated Oct 29, 2026 · NCT07102381

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

RecruitingPhase 1/2
  • Massachusetts General Hospital, Boston
Ages 18 and older · All sexes · Updated Oct 28, 2026 · NCT07109726

Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic

RecruitingPhase 1
  • Massachusetts General Brigham, Boston
Ages 18 and older · All sexes · Updated Oct 23, 2026 · NCT07807345

A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors

RecruitingPhase 1
  • Dana-Farber Cancer Institute, Boston
Ages 18 and older · All sexes · Updated Oct 22, 2026 · NCT07383506

The Cancer of the Pancreas Screening-5 CAPS5)Study

RecruitingPhase 3
  • Dana Farber Cancer Center, Harvard University, Boston
Ages 18 and older · All sexes · Updated Oct 22, 2026 · NCT02000089

Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)

RecruitingPhase 1/2
  • Dana-Farber Cancer Institute ( Site 0050), Boston
Ages 18 and older · All sexes · Updated Oct 21, 2026 · NCT06686394

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

RecruitingPhase 3
  • Brigham and Women's Hospital, Boston
  • Dana Farber Cancer Institute, Boston
Ages 18 and older · All sexes · Updated Oct 19, 2026 · NCT07062965

Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer.

RecruitingPhase 2
  • Dana Farber Cancer Institute, Boston
Ages 70 and older · All sexes · Updated Oct 16, 2026 · NCT04305834

Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

RecruitingPhase 1/2
  • Massachusetts General Hospital, Boston
Ages 18 and older · All sexes · Updated Oct 15, 2026 · NCT06239194

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

RecruitingPhase 1
  • Dana Farber Cancer Institute, Boston
Ages 18 and older · All sexes · Updated Oct 13, 2026 · NCT06293898

A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies

RecruitingPhase 1/2
  • Research Site, Boston
Ages 18 and older · All sexes · Updated Oct 13, 2026 · NCT05123482

Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors

RecruitingPhase 1/2
  • Beth Israel Deaconess Medical Center, Boston
  • Dana-Farber Cancer Institute, Boston
Ages 18 and older · All sexes · Updated Oct 13, 2026 · NCT06993844

Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer

RecruitingPhase 1/2
  • Dana-Farber Cancer Institute, Boston
Ages 18 and older · All sexes · Updated Oct 9, 2026 · NCT05386108

Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

RecruitingPhase 3
  • Massachusetts General Hospital Cancer Center, Boston
Ages 18 and older · All sexes · Updated Oct 9, 2026 · NCT06757634

TRUDI: TDXD+Durva in HER2+/Low IBC

RecruitingPhase 2
  • Brigham and Women's Hospital, Boston
  • Dana Farber Cancer Institute, Boston
Ages 18 and older · Women · Updated Oct 9, 2026 · NCT05795101

Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies

RecruitingPhase 1/2
  • Research Site, Boston
Ages 18 to 130 · All sexes · Updated Oct 5, 2026 · NCT05417594

A Study of PHST001 in Advanced Solid Tumors

RecruitingPhase 1
  • Dana Farber Cancer Institute, Boston
Ages 18 and older · All sexes · Updated Oct 5, 2026 · NCT06840886

Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors

RecruitingPhase 1
  • Massachusetts General Hospital, Boston
  • Dana-Farber Cancer Institute, Boston
Ages 18 and older · All sexes · Updated Oct 5, 2026 · NCT06784193

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

RecruitingPhase 1/2
  • Massachusetts General Hospital, Boston
  • Dana Farber Cancer Institute, Boston
Ages 12 and older · All sexes · Updated Oct 2, 2026 · NCT04585750

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

RecruitingPhase 1
  • Massachusetts General Hospital, Boston
  • Dana-Farber Cancer Insitute, Boston
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT06625775

A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer

RecruitingPhase 1/2
  • Massachusetts General Hospital, Boston
  • Dana-Farber Cancer Institute, Boston
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT07701941

A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer

RecruitingPhase 2
  • Massachusetts General Hospital, Boston
  • Dana-Farber Cancer Institute, Boston
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT06369285

A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

RecruitingPhase 1
  • Research Site, Boston
  • Research Site, Boston
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT05877599

IKS014 in Advanced Solid Tumors That Express HER2

RecruitingPhase 1
  • Dana Farber Cancer Institute, Boston
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT05872295

Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases

RecruitingPhase 2
  • Brigham and Women's Hospital, Boston
  • Dana Farber Cancer Institute, Boston
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT04899908

A Phase 1/1b Study of IAM1363 in HER2 Cancers

RecruitingPhase 1
  • Massachusetts General Hospital, Boston
  • Dana Farber Cancer Institute, Boston
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT06253871

Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer

RecruitingPhase 1
  • Dana-Farber Cancer Institute, Boston
Ages 18 and older · All sexes · Updated Sep 2, 2026 · NCT06488378

Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors

RecruitingPhase 1/2
  • Dana Farber Cancer Institute, Boston
Ages 18 to 100 · All sexes · Updated Aug 27, 2026 · NCT06726148

TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd

RecruitingPhase 2
  • Dana-Farber Cancer Institute, Boston
Ages 18 and older · All sexes · Updated Aug 26, 2026 · NCT06533826

PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)

RecruitingPhase 2
  • Dana-Farber Cancer Institute, Boston
Ages 18 and older · All sexes · Updated Aug 26, 2026 · NCT07222215

Optimizing Surgical Decisions in Young Adults With Breast Cancer

Recruiting
  • Dana-Farber Cancer Institute, Boston
Ages 18 to 44 · Women · Updated Aug 19, 2026 · NCT06275126

ATEMPT 2.0: Adjuvant T-DM1 vs TH

RecruitingPhase 2
  • Dana Farber Cancer Institute, Boston
  • Massachusetts General Hospital, Boston
Ages 18 and older · All sexes · Updated Aug 19, 2026 · NCT04893109

FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer

RecruitingPhase 1
  • Massachusetts General Hospital, Boston
Ages 18 and older · All sexes · Updated Aug 12, 2026 · NCT05304962

Supporting Health Including Endocrine Treatment for Long Duration

Recruiting
  • Dana-Farber Cancer Institute, Boston
Ages 18 to 49 · Women · Updated Aug 10, 2026 · NCT07482384

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

RecruitingPhase 2/3
  • Massachusetts General Hospital, Boston
  • Dana-Farber Cancer Institute, Boston
Ages 18 and older · All sexes · Updated Aug 10, 2026 · NCT06926868

Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects

RecruitingPhase 3
  • Massachusetts General Hospital Cancer Center, Boston
Ages 18 to 100 · All sexes · Updated Aug 6, 2026 · NCT05232916

DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs

RecruitingPhase 2
  • Dana-Farber Cancer Institute, Boston
Ages 18 and older · All sexes · Updated Aug 6, 2026 · NCT06176261

The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer

RecruitingPhase 2
  • Dana-Farber Cancer Institute, Boston
Ages 18 and older · All sexes · Updated Aug 6, 2026 · NCT06439693

Comparison of Breast Cancer Screening With CESM to DBT in Women With Dense Breasts

RecruitingHealthy volunteers welcome
  • Massachusetts General Hospital, Boston
Ages 45 to 74 · Women · Updated Jul 31, 2026 · NCT05625659

Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers

RecruitingPhase 1
  • Massachusetts General Hospital, Boston
Ages 18 to 100 · All sexes · Updated Jul 29, 2026 · NCT06562192

Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial

RecruitingPhase 2
  • Dana-Farber Cancer Institute, Boston
Ages 18 to 55 · Women · Updated Jul 27, 2026 · NCT06184750

A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

RecruitingPhase 2
  • Tufts Medical Center, Boston
  • Massachusetts General Hospital, Boston
  • Dana-Farber Cancer Institute, Boston
Ages 8 and older · All sexes · Updated Jul 27, 2026 · NCT05503797

TeleHealth Resistance Exercise Intervention to Preserve Dose Intensity and Vitality in Elder Breast Cancer Patients

Recruiting
  • Dana Farber Cancer Institute, Boston
Ages 65 and older · Women · Updated Jul 17, 2026 · NCT05535192

Chemotherapy-induced Cognitive and Brain Changes in Older Adults With Breast Cancer

RecruitingHealthy volunteers welcome
  • Massachusetts General Hospital, Boston
Ages 60 and older · Women · Updated Jul 16, 2026 · NCT02290834

First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

RecruitingPhase 1/2
  • Massachusetts General Hospital, Boston
  • Dana-Farber Cancer Institute, Boston
Ages 18 and older · All sexes · Updated Jul 7, 2026 · NCT05768139

Clonal Hematopoiesis Chemotherapy and Radiation Effects Study

RecruitingObservational study
  • Dana-Farber Cancer Institute, Boston
Ages 18 and older · All sexes · Updated Jun 30, 2026 · NCT07675967

A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors

RecruitingPhase 1/2
  • Beth Israel Deaconess Medical Center, Boston
  • Dana-Farber Cancer Institute, Boston
Ages 18 and older · All sexes · Updated Jun 29, 2026 · NCT05377996

A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study

RecruitingPhase 2
  • GSK Investigational Site, Boston
Ages 18 and older · All sexes · Updated Jun 24, 2026 · NCT04641247

Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer

RecruitingPhase 1/2
  • Massachusetts General Hospital, Boston
Ages 18 and older · Women · Updated Jun 22, 2026 · NCT05573126

Scalp Cooling in MBC

RecruitingPhase 2
  • Brigham and Women's Hospital, Boston
  • Dana Farber Cancer Institute, Boston
Ages 18 and older · All sexes · Updated Jun 18, 2026 · NCT04986579

Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer

RecruitingPhase 3
  • Dana-Farber Cancer Institute, Boston
Ages 18 and older · All sexes · Updated Jun 12, 2026 · NCT05950945

ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer

RecruitingPhase 1/2
  • Dana-Farber Cancer Institute, Boston
Ages 18 and older · All sexes · Updated Jun 10, 2026 · NCT07198724

Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation

RecruitingPhase 1
  • Dana Farber Cancer Institute, Boston
Ages 18 and older · All sexes · Updated Jun 8, 2026 · NCT04890613

Oncoplastic Surgery Outcomes Database

RecruitingObservational study
  • Tufts Medical Center, Boston
Ages 18 and older · Women · Updated May 27, 2026 · NCT07597837

Efficacy of Trastuzumab Deruxtecan in Metastatic Breast Cancer With Different HER2 Expression Patterns

RecruitingObservational study
  • Dana-Farber Cancer Institute, Harvard Medical School, Boston
Ages 18 to 80 · Women · Updated May 22, 2026 · NCT06551220

Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial

RecruitingPhase 2
  • Massachusetts General Hospital Cancer Center, Boston
Ages 18 and older · Women · Updated May 6, 2026 · NCT03990896

Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

RecruitingPhase 2
  • Dana-Farber Cancer Institute, Boston
Ages 18 and older · All sexes · Updated May 4, 2026 · NCT04434040

VS-6766+Abema+Fulv in Met HR+/HER- BC

RecruitingPhase 1/2
  • Brigham and Women's Hospital, Boston
  • Dana Farber Cancer Institite, Boston
Ages 18 and older · All sexes · Updated Apr 30, 2026 · NCT05608252

Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

RecruitingPhase 2
  • Dana Farber Cancer Institute, Boston
Ages 18 and older · All sexes · Updated Apr 29, 2026 · NCT04468061

Remote Monitoring and Symptom Management Digital Application

Recruiting
  • Massachusetts General Hospital, Boston
Ages 18 and older · All sexes · Updated Apr 28, 2026 · NCT07553572

Exercise in Metastatic Breast Cancer: EMBody

Recruiting
  • Dana-Farber Cancer Institute, Boston
Ages 18 and older · All sexes · Updated Apr 27, 2026 · NCT05468034

A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer

RecruitingPhase 1
  • Beth Israel Deaconess Medical Center, Boston
  • Dana-Farber Cancer Institute, Boston
Ages 18 and older · Women · Updated Apr 22, 2026 · NCT05683418

Individualizing Approaches to Surveillance Mammography in Older Breast Cancer Survivors - The I-MAMMO Study

RecruitingPhase 2Healthy volunteers welcome
  • Dana-Farber Cancer Institute, Boston
Ages 80 and older · Women · Updated Apr 22, 2026 · NCT07123649

SDM POSSIBLE: A Breast Cancer Treatment Decision Aid for Women 70+ With Low-Risk Stage I Breast Cancers

Recruiting
  • Beth Israel Deaconess Medical Center, Boston
  • Brigham and Women's Hospital, Boston
  • Dana Farber Cancer Institute, Boston
Ages 18 and older · All sexes · Updated Apr 7, 2026 · NCT06896474

A Study of DB-1310 in Advanced/Metastatic Solid Tumors

RecruitingPhase 1/2
  • Dana-Farber Cancer Institute, Boston
Ages 18 and older · All sexes · Updated Apr 6, 2026 · NCT05785741

Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer

RecruitingPhase 1/2
  • Dana-Farber Cancer Institute, Boston
Ages 18 and older · All sexes · Updated Apr 1, 2026 · NCT05735080

Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Hypertension Receiving Bevacizumab for Breast Cancer

RecruitingObservational study
  • Eastern Cooperative Oncology Group, Boston
All ages · All sexes · Updated Mar 27, 2026 · NCT02610413

Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Peripheral Neuropathy Receiving Paclitaxel for Breast Cancer

RecruitingObservational study
  • Eastern Cooperative Oncology Group, Boston
All ages · All sexes · Updated Mar 27, 2026 · NCT02610439

A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

RecruitingPhase 1/2
  • Massachusetts General Hospital, Boston
Ages 18 and older · All sexes · Updated Mar 27, 2026 · NCT06395519

Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Congestive Heart Failure Receiving Therapy for Breast Cancer

RecruitingObservational study
  • Eastern Cooperative Oncology Group, Boston
All ages · All sexes · Updated Mar 27, 2026 · NCT02610426

A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer

RecruitingPhase 2
  • Dana Farber Cancer Institute (Data Collection Only), Boston
Ages 18 and older · All sexes · Updated Feb 25, 2026 · NCT06099769

Impact of Pectoral Versus Paravertebral Blocks on Pain and Physical Well-Being in Implant-Based Breast Reconstruction

Recruiting
  • Massachusetts General Hospital, Boston
Ages 18 and older · All sexes · Updated Jan 22, 2026 · NCT07209436

Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years

RecruitingPhase 4
  • Massachussets General Hospital, Boston
Ages 18 to 64 · All sexes · Updated Jan 22, 2026 · NCT04373564

Refining Local-Regional Therapy for IBC

Recruiting
  • Dana Farber Cancer Institute, Boston
Ages 18 and older · Women · Updated Dec 29, 2025 · NCT04636710

Targeted Palliative Care Intervention for Patients With Metastatic Breast Cancer

Recruiting
  • Massachusetts General Hospital, Boston
Ages 18 and older · All sexes · Updated Nov 18, 2025 · NCT06795529

Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer

RecruitingPhase 2
  • Massachusetts General Hospital, Boston
Ages 18 and older · All sexes · Updated Nov 10, 2025 · NCT04553770

Strength After Breast Cancer

Recruiting
  • MGH Institute of Health Professions, Boston
Ages 18 and older · Women · Updated Oct 20, 2025 · NCT06052488

A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors

RecruitingPhase 1/2
  • Dana Farber Cancer Institute, Boston
Ages 18 and older · All sexes · Updated Sep 24, 2025 · NCT05941507

Comprehensive Outcomes for After Cancer Health

RecruitingHealthy volunteers welcome
  • Dana Farber Cancer Institute, Boston
Ages 18 and older · All sexes · Updated Dec 11, 2024 · NCT05349227

About Breast Cancer

Breast cancer is a cancer that starts in the breast tissue, when cells change and grow out of control. Learn about the types, diagnosis, and treatments.

More about Breast Cancer on MedlinePlus

Breast Cancer trials in other cities

Other studies in Boston

From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.